PTP inhibitor 1 structure
|
Common Name | PTP inhibitor 1 | ||
---|---|---|---|---|
CAS Number | 2632-13-5 | Molecular Weight | 229.071 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 306.7±17.0 °C at 760 mmHg | |
Molecular Formula | C9H9BrO2 | Melting Point | 69-71 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 139.3±20.9 °C | |
Symbol |
GHS05, GHS07 |
Signal Word | Danger |
Use of PTP inhibitor 1PTP inhibitor 1 is a protein tyrosine phosphatase (PTP) inhibitor, with anti-angiogenic effect[1]. |
Name | 2-bromo-1-(4-methoxyphenyl)ethanone |
---|---|
Synonym | More Synonyms |
Description | PTP inhibitor 1 is a protein tyrosine phosphatase (PTP) inhibitor, with anti-angiogenic effect[1]. |
---|---|
Related Catalog | |
Target |
PTP[1] |
In Vitro | PTP inhibitor 1 exhibits anti-angiogenic activity with an IC50 of 3.7 μM for HUVECs[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 306.7±17.0 °C at 760 mmHg |
Melting Point | 69-71 °C(lit.) |
Molecular Formula | C9H9BrO2 |
Molecular Weight | 229.071 |
Flash Point | 139.3±20.9 °C |
Exact Mass | 227.978592 |
PSA | 26.30000 |
LogP | 2.27 |
Vapour Pressure | 0.0±0.6 mmHg at 25°C |
Index of Refraction | 1.554 |
Storage condition | 2-8°C |
Symbol |
GHS05, GHS07 |
---|---|
Signal Word | Danger |
Hazard Statements | H314-H335 |
Precautionary Statements | P261-P280-P305 + P351 + P338-P310 |
Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
Hazard Codes | Xi:Irritant |
Risk Phrases | R36/37/38 |
Safety Phrases | S26-S27-S28-S36/37/39-S45-S37/39 |
RIDADR | UN 3261 8/PG 2 |
WGK Germany | 3 |
Packaging Group | III |
Hazard Class | 8 |
HS Code | 29147090 |
Precursor 9 | |
---|---|
DownStream 10 | |
HS Code | 2914700090 |
---|---|
Summary | HS: 2914700090 halogenated, sulphonated, nitrated or nitrosated derivatives of ketones and quinones, whether or not with other oxygen function Tax rebate rate:9.0% Supervision conditions:none VAT:17.0% MFN tariff:5.5% General tariff:30.0% |
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
J. Med. Chem. 54 , 4042-56, (2011) Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, bein... |
|
QSAR study and conformational analysis of 4-arylthiazolylhydrazones derived from 1-indanones with anti-Trypanosoma cruzi activity.
Eur. J. Pharm. Sci. 78 , 190-7, (2015) A set of 4-arylthiazolylhydrazones derived from 1-indanones (TZHs) previously synthesized and assayed against Trypanosoma cruzi, the causative agent of Chagas disease, were explored in terms of confor... |
|
Synthesis of diblock copolymers bearing p-methoxyphenacyl side groups.
Polym. Chem. 2(10) , 2284-2292, (2011)
|
α-Bromo-4'-methoxyacetophenone |
p-methoxyphenacyl bromide |
4'-Methoxyphenacyl Bromide |
4-Methoxyphenacyl Br |
ω-Bromo-4-methoxyacetophenone |
2-Bromo-1-(4-methoxyphenyl)ethanone |
4-Methoxyphenacyl bromide |
2-Bromo-4′-methoxyacetophenone |
2-Bromo-4‘-methoxyacetophenone |
Acetophenone, 2-bromo-4'-methoxy- |
2-Bromo-4'-methoxyacetophenone |
MFCD00465443 |
2-bromo-1-(4'-methoxy-phenyl)-ethanone |
2-Bromo-4'-methoxyacetophenone, Pract. |
Ethanone,2-bromo-1-(4-methoxyphenyl) |
1-(4-methoxyphenyl)-2-bromo-ethan-1-one |
Ethanone, 2-bromo-1-(4-methoxyphenyl)- |
EINECS 220-118-8 |
4-(Bromoacetyl)anisole |